Preventing Cryptococcosis—Shifting the Paradigm in the Era of Highly Active Antiretroviral Therapy

Meya, David; Rajasingham, Radha; Nalintya, Elizabeth; Tenforde, Mark; Jarvis, Joseph N

doi:10.1007/s40475-015-0045-z

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Preventing Cryptococcosis—Shifting the Paradigm in the Era of Highly Active Antiretroviral Therapy

Published Date:

2015

Publisher's site:

http://dx.doi.org/10.1007/s40475-015-0045-z New Site Icon

Source:

Curr Trop Med Rep. 2(2):81-89.

[PDF-261.55 KB]

Details:

Personal Authors:

Meya, David ; Rajasingham, Radha ; Nalintya, Elizabeth ; Tenforde, Mark ; Jarvis, Joseph N ;

Keywords:

[+]

Pubmed ID:

25960942

Pubmed Central ID:

PMC4412515

Description:

Cryptococcosis remains a significant cause of morbidity and mortality among HIV-infected patients, especially in sub-Saharan Africa where it causes up to 20 % of AIDS-related deaths in HIV programs. A new, highly sensitive, and affordable point of care diagnostic test for cryptococcal infection, the lateral flow assay, can detect early sub-clinical cryptococcosis especially in areas with limited laboratory infrastructure. With a prevalence of detectable sub-clinical cryptococcal infection averaging 7.2 % (95 % CI 6.8-7.6 %) among 36 cohorts with CD4 <100 cells/μL in Africa, together with data showing that preemptive fluconazole prevents overt cryptococcal disease in this population, implementing a screen and treat strategy as part of HIV care practice among patients with CD4 <100 cells/μL could prevent the incidence of often fatal cryptococcal meningitis in the setting of the HIV pandemic.

Document Type:

Journal Article

Collection(s):

CDC Public Access

Funding:

U01 AI089244/AI/NIAID NIH HHS/United States
U01 GH000517/GH/CGH CDC HHS/United States
P30 AI045008/AI/NIAID NIH HHS/United States
R01 AI078934/AI/NIAID NIH HHS/United States
R01 AI108479/AI/NIAID NIH HHS/United States
087540/Wellcome Trust/United Kingdom

Supporting Files:

40475_2015_Article_45.nxml

application/octet-stream

No Related Documents.

You May Also Like:

CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis

Personal Author:

Ford, Nathan; Shubber, Zara; Jarvis, Joseph N; Chiller, Tom; Greene, Greg; Migone, Chantal; Vitoria, Marco; Doherty, Meg; Meintjes, Graeme;

Published:

Mar 04 2018

Source:

Clin Infect Dis. 2018; 66(Suppl 2):S152-S159.

Description:

Background : Current guidelines recommend screening all people living with human immunodeficiency virus (PLHIV) who have a CD4 count ≤100 cells/µL for cryptococcal antigen (CrAg) to identify those patients who could benefit from preemptive flucona...

File Type:

[PDF - 2.31 MB]
Evolution of Cryptococcal Antigen Testing: What is new?

Personal Author:

Nalintya, Elizabeth; Kiggundu, Reuben; Meya, David;

Published:

Apr 12 2016

Source:

Curr Fungal Infect Rep. 10(2):62-67.

Description:

Over the last decade, an upsurge in both the frequency and severity of fungal infections due to the HIV/AIDS epidemic and the use of immunosuppressive therapy has occurred. Even diagnostic methods like culture and microscopy, which have low sensitivi...

File Type:

[PDF - 308.89 KB]
Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children; recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics

Personal Author:

Danner, Susie P.; Dominguez, Kenneth L.; Mofenson, Lynne M.; Nesheim, Steven R.;

Corporate Author:

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.); American Academy of Pediatrics; Centers for Disease Control and Prevention (U.S.); HIV Medicine Association; National Institutes of Health (U.S.); Pediatric Infectious Diseases Society;

Published:

September 4, 2009

Source:

MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 2009; 58(RR-11):1-166.

Series:

Morbidity and mortality weekly report. Recommendations and reports ; v. 58, no. RR-11
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 58, no. RR-11

Description:

This report updates and combines into one document earlier versions of guidelines for preventing and treating opportunistic infections (OIs) among HIV-exposed and HIV-infected children, last published in 2002 and 2004, respectively. These guidelines ...

Status:

superseded

File Type:

[PDF - 2.08 MB]
Screening HIV-Infected Patients with Low CD4 Counts for Cryptococcal Antigenemia prior to Initiation of Antiretroviral Therapy: Cost Effectiveness of Alternative Screening Strategies in South Africa

Personal Author:

Larson, Bruce A.; Rockers, Peter C.; Bonawitz, Rachael; Sriruttan, Charlotte; Glencross, Deborah K.; Cassim, Naseem; Coetzee, Lindi M.; Greene, Gregory S.; Chiller, Tom M.; Vallabhaneni, Snigdha; Long, Lawrence; van Rensburg, Craig; Govender, Nelesh P.;

Published:

Jul 08 2016

Source:

PLoS One. 11(7).

Description:

Background : In 2015 South Africa established a national cryptococcal antigenemia (CrAg) screening policy targeted at HIV-infected patients with CD4+ T-lymphocyte (CD4) counts <100 cells/ μl who are not yet on antiretroviral treatment (ART). Two scr...

File Type:

[PDF - 1.38 MB]
Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents : recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America

Corporate Author:

Centers for Disease Control and Prevention (U.S.); National Institutes of Health (U.S.); HIV Medicine Association.; United States. AIDSinfo; Opportunistic Infections Working Group.;

Published:

October 21, 2015; last reviewed May 7, 2013

Description:

Sections updated frequently: see "What's New in the Guidelines" at https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/392/whats-new : The Guidelines for the Prevention and Treatment o...

Status:

current

File Type:

[PDF - 5.97 MB]